JP2019088334A5 - - Google Patents

Download PDF

Info

Publication number
JP2019088334A5
JP2019088334A5 JP2019052699A JP2019052699A JP2019088334A5 JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5 JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019052699 A JP2019052699 A JP 2019052699A JP 2019088334 A5 JP2019088334 A5 JP 2019088334A5
Authority
JP
Japan
Prior art keywords
cells
hla
genetically modified
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019052699A
Other languages
English (en)
Japanese (ja)
Other versions
JP7294838B2 (ja
JP2019088334A (ja
Filing date
Publication date
Priority claimed from JP2018028816A external-priority patent/JP6502544B2/ja
Application filed filed Critical
Publication of JP2019088334A publication Critical patent/JP2019088334A/ja
Publication of JP2019088334A5 publication Critical patent/JP2019088334A5/ja
Priority to JP2021068195A priority Critical patent/JP7379410B2/ja
Application granted granted Critical
Publication of JP7294838B2 publication Critical patent/JP7294838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019052699A 2012-07-31 2019-03-20 Hla g改変された細胞および方法 Active JP7294838B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021068195A JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677739P 2012-07-31 2012-07-31
US61/677,739 2012-07-31
JP2018028816A JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018028816A Division JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068195A Division JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Publications (3)

Publication Number Publication Date
JP2019088334A JP2019088334A (ja) 2019-06-13
JP2019088334A5 true JP2019088334A5 (https=) 2019-09-26
JP7294838B2 JP7294838B2 (ja) 2023-06-20

Family

ID=50028654

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015525519A Active JP6297559B2 (ja) 2012-07-31 2013-07-30 Hlag改変された細胞および方法
JP2018028816A Active JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法
JP2019052699A Active JP7294838B2 (ja) 2012-07-31 2019-03-20 Hla g改変された細胞および方法
JP2021068195A Active JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015525519A Active JP6297559B2 (ja) 2012-07-31 2013-07-30 Hlag改変された細胞および方法
JP2018028816A Active JP6502544B2 (ja) 2012-07-31 2018-02-21 Hla g改変された細胞および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021068195A Active JP7379410B2 (ja) 2012-07-31 2021-04-14 Hla g改変された細胞および方法

Country Status (10)

Country Link
US (4) US9714280B2 (https=)
EP (4) EP2880054B1 (https=)
JP (4) JP6297559B2 (https=)
KR (4) KR101923632B1 (https=)
CN (2) CN113151179A (https=)
AU (2) AU2013296564C1 (https=)
CA (1) CA2882028C (https=)
ES (2) ES2837487T3 (https=)
SG (1) SG11201500799YA (https=)
WO (1) WO2014022423A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
DK3129487T3 (da) 2014-04-09 2020-11-30 Dna Twopointo Inc Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US9808490B2 (en) * 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US20220241345A1 (en) * 2015-10-02 2022-08-04 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
US12544406B2 (en) 2015-10-02 2026-02-10 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
CA3001312A1 (en) 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
BR112019001344A2 (pt) 2016-07-26 2019-04-30 The University Of North Carolina At Chapel Hill tolerância imunológica mediada por vetor no olho
WO2018132479A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
JP7241161B2 (ja) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
TW202043463A (zh) * 2018-12-14 2020-12-01 比利時商普羅米修亞生物科技股份有限公司 包含表現hla-e之肝先驅細胞之細胞組成物
TW202035682A (zh) 2018-12-14 2020-10-01 比利時商普羅米修亞生物科技股份有限公司 表現hla-g之肝先驅細胞及取得包含該等細胞之此等細胞組成物之方法與其用途
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
JP2023513263A (ja) * 2020-02-10 2023-03-30 ルビウス セラピューティクス, インコーポレイテッド Hla-gポリペプチドを含む操作された赤血球系細胞およびその使用方法
WO2021241658A1 (ja) * 2020-05-26 2021-12-02 株式会社ヘリオス 低免疫原性細胞
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
JP2024540987A (ja) * 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5744320A (en) 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
US6982431B2 (en) 1998-08-31 2006-01-03 Molecular Devices Corporation Sample analysis systems
US6031094A (en) 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
CN1302115C (zh) 2001-04-23 2007-02-28 埃麦克萨有限公司 电穿孔用缓冲溶液及上述溶液的使用方法
EP1543110A4 (en) 2002-05-17 2006-09-06 Sinai School Medicine POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL
EP2341134B1 (en) 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
WO2005034624A2 (en) 2003-05-21 2005-04-21 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
PT1675956E (pt) * 2003-10-21 2010-11-04 Merck Serono Sa Sequência mínima de adn que actua como um isolador de cromatina e sua utilização na expressão de proteína
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
KR101271884B1 (ko) * 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN103555655B (zh) * 2005-10-21 2018-02-27 细胞研究私人有限公司 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090156532A1 (en) * 2006-01-24 2009-06-18 The University Of Chicago SNP BINDING SITE FOR microRNAs IN HLA-G
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
EP2087107A2 (en) 2006-10-30 2009-08-12 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and functional expression
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法
US8592211B2 (en) 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
CN103333861A (zh) * 2013-06-03 2013-10-02 浙江省台州医院 特异性表达hla-g1抗原的细胞株k562
CN111808819A (zh) * 2020-05-26 2020-10-23 台州恩泽医疗中心(集团) 表达hla-g3异构体标准蛋白的细胞株及其应用

Similar Documents

Publication Publication Date Title
JP2019088334A5 (https=)
JP2015529457A5 (https=)
JP6502544B2 (ja) Hla g改変された細胞および方法
JP6970106B2 (ja) Vcnエンハンサー組成物およびその使用方法
ES2601845T3 (es) Aislamiento y purificación de células madre hematopoyéticas a partir de lipoaspirados post-liposucción
JP2021534806A (ja) ユニバーサルドナー細胞
JP2020509780A (ja) 細胞並びにその使用方法及び製造方法
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CN114026225A (zh) 安全的免疫隐形细胞
IL293552A (en) Modulators of the immune escape mechanism for universal cell therapy
US20230235280A1 (en) Modified stem cells and methods of use thereof
JP2022551478A (ja) 持続的トランスジーン発現を伴う細胞
JP7016556B2 (ja) 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途
Lim et al. Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells
CA3100262A1 (en) Compositions and methods for haematopoietic stem cell transplantation
JP2024535677A5 (https=)
CN117716026A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
WO2016112779A1 (en) Modified cells evoking reduced immunogenic responses
JP5745419B2 (ja) 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法
JP6691756B2 (ja) 合成ペプチドを用いた神経幹細胞の生産方法
JP2021503008A (ja) 造血幹細胞および前駆細胞移植療法のための組成物および方法
CN120615119A (zh) 用于同种异体细胞疗法以覆盖全球、种族或特定疾病群体的免疫相容细胞
CN116396940A (zh) 造血干祖细胞及其制备方法和用途
Carretero et al. Applicability of bioengineered human skin: from preclinical skin humanized mouse models to clinical regenerative therapies
CN100408677C (zh) 一种bdnf基因修饰的间充质干细胞的构建方法